EVENITY® is indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. Read More

The anabolic effect of EVENITY® wanes after 12 monthly doses of therapy. Therefore, the duration of EVENITY® use should be limited to 12 monthly doses. If osteoporosis therapy remains warranted, continued therapy with an antiresorptive agent should be considered. Close

Patients like yours could benefit from EVENITY®



Multiple risk factors, has not experienced fracture

Postmenopausal Osteoporosis History:

  • Currently receiving treatment with an oral bisphosphonate and is on Medicare Part B
  • Has not experienced a fracture despite multiple risk factors, including mother who suffered a hip fracture at age 75, very low BMD, and advanced age
  • Current BMD: -3.0
  • BMD 2 years ago: -3.1

Hypothetical patient


Very low BMD and her maternal history of hip fracture are just two signs that Barbara’s first fracture could be sooner than she thinks.

Patients like Barbara need to help reduce the risk of a fracture


  • Barbara is 73 and lives in a very active social community
  • She enjoys meeting her neighbors at local events, most of which are within walking distance
  • As she nears the age her mother was when she suffered a hip fracture, Barbara herself is becoming nervous about fractures
  • She worries a fracture may affect her social life and mobility
  • Her doctor recently suggested she get a DXA scan so they can reassess her BMD

Despite Barbara’s current therapy, her BMD remains very low.

Patients like Barbara, with multiple risk factors for fracture, need to build bone quickly. Now is a good time to discuss the benefits of a treatment that will rapidly build new bone within 12 months.


Active and treatment naive

Postmenopausal Osteoporosis History:

  • Was unaware that she sustained a vertebral fracture 2 months ago
  • Not currently being treated for osteoporosis
  • Current BMD: -2.59
  • BMD 2 years ago: -2.43

Hypothetical patient


Nancy never thought her back pain was the result of an osteoporosis-related vertebral fracture.1

Another fracture can impact patients like Nancy


  • Nancy is 65 years old, recently retired from teaching, and is on Medicare
  • She and her husband enjoy hiking now that they both are retired
  • But Nancy has been in constant pain from the undiagnosed fracture
  • When she visited her family practitioner, Nancy was shocked to learn the pain was from a vertebral fracture
  • She worries that another fracture could limit their future hiking adventures

Since Nancy is at the highest risk for fracture in the year after her first one, she is looking for a treatment that will rapidly build strong new bone within 12 months.

Patients like Nancy don't always know their pain could be connected to a fracture. It's important to discuss with postmenopausal osteoporosis patients their risk of fracture and treatment options.


Fractured while on a bisphosphonate

Postmenopausal Osteoporosis History:

  • Prescribed a bisphosphonate 12 months ago after a vertebral fracture
  • Recently suffered a wrist fracture even though she takes the bisphosphonate as prescribed
  • Current BMD: -3.31
  • BMD 2 years ago: -3.47

Hypothetical patient


Betsey's osteoporosis-related fracture is an indicator that her bones have deteriorated.2

After a fracture, many women like Betsey are concerned about suffering from another2


  • At age 71, Betsey recently lost her husband and currently lives alone
  • She takes care of her 4-year-old twin grandchildren while their parents work, and she loves traveling
  • Betsey is worried what an additional fracture could mean
  • Her doctor wants to prescribe a bone builder

Betsey's first fracture was soon followed by another, and she now needs a bone-building treatment that can decrease her risk of another fracture.

Having a second fracture while being treated for osteoporosis can be confusing and frightening. This is a good time to talk with patients like Betsey about the possibility of transitioning to a bone-building treatment.

The 2020 AACE/ACE guidelines state EVENITY® should be considered as initial therapy for appropriate patients

Appropriate patients are those at very high risk for fracture as defined by:3
  • Recent fracture (within the last 12 months)
  • Fractures while on approved osteoporosis therapy
  • Multiple fractures
  • Fractures while on drugs causing skeletal harm
  • Very low T-score (eg, < -3.0)
  • Very high fracture probability by FRAX(eg, major osteoporotic fracture > 30%, hip fracture > 4.5%)
  • High risk for falls or history of harmful falls
EVENITY® is FDA approved for the treatment of postmenopausal women with osteoporosis at high risk for fracture

High risk for fracture is defined in the EVENITY®Prescribing Information as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.

  • AACE/ACE guidelines recommend

    following EVENITY® with an antiresorptive treatment3

  • AACE/ACE guidelines support

    ongoing monitoring to assess treatment progress3

AACE = American Association of Clinical Endocrinologists; ACE = American College of Endocrinology; FRAX = fracture risk assessment tool.
FRAX is a trademark owned by the International Osteoporosis Foundation.

PMO = postmenopausal osteoporosis.



EVENITY® may increase the risk of myocardial infarction, stroke and cardiovascular death. EVENITY® should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors. Monitor for signs and symptoms of myocardial infarction and stroke and instruct patients to seek prompt medical attention if symptoms occur. If a patient experiences a myocardial infarction or stroke during therapy, EVENITY® should be discontinued.

Back to Top

References: 1. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25:2359-2381. 2. US Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: US Department of Health and Human Services. Office of the Surgeon General; 2004. 3. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis—2020 Update. Endocr Pract. 2020;26(suppl 1):1-46.